secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001193125-26-113893
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports 2025 net loss $151.6M, cash $270M; Phase 3 PROACT 1 on track for mid-2026 enrollment
--------------------------------------------------------------------------------

- Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.
- Cash and marketable securities $270.0M at Dec 31, 2025, down from $358.3M; runway into mid-2027.
- Phase 3 PROACT 1 enrollment for accelerated approval (n~360) on track for mid-2026; top-line eGFR slope data Q2 2027.
- FDA confirmed in July 2025 Type B meeting that eGFR slope can serve as surrogate endpoint for accelerated approval.
- Positive Phase 2 REGEN-007 results presented at ASN Kidney Week 2025 and published in CJASN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/0001193125-26-113893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/prok-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-113893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer